Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RHB-106 is a proprietary, flavorless, odorless, solid oral encapsulated formulation developed for bowel preparation and cleansing of the gastrointestinal tract prior to abdominal procedures and diagnostic tests, such as colonoscopy, barium enema, or virtual colonoscopy, as well as surgical interventions like laparotomy. Its novel solid oral pill format avoids the unpleasant taste typical of current bowel preparations, aiming to improve patient compliance and outcome. The mechanism of action is as a bowel purgative, with its composition designed to induce cleansing through osmotic or laxative effects, but the exact active ingredients are undisclosed. No molecular target is described for this formulation. RHB-106 is under development, with positive results from a Phase 2a study showing significant improvement in patient response and comparable bowel cleansing efficacy[1][2][7][10].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on RHB-106.